Compare AUB & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUB | ERAS |
|---|---|---|
| Founded | 1902 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.3B |
| IPO Year | 2005 | 2021 |
| Metric | AUB | ERAS |
|---|---|---|
| Price | $40.17 | $14.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $45.63 | $24.11 |
| AVG Volume (30 Days) | 1.3M | ★ 4.9M |
| Earning Date | 10-20-2026 | 11-16-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 2.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.59 | N/A |
| Revenue Next Year | $4.17 | N/A |
| P/E Ratio | $20.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.87 | $2.11 |
| 52 Week High | $43.62 | $24.28 |
| Indicator | AUB | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 48.50 |
| Support Level | $36.47 | $13.47 |
| Resistance Level | $43.20 | $15.71 |
| Average True Range (ATR) | 0.87 | 1.02 |
| MACD | 0.19 | 0.05 |
| Stochastic Oscillator | 70.16 | 64.98 |
Atlantic Union Bankshares Corp is a financial and bank holding company based in the U.S. Through its community bank subsidiary and non-bank financial services affiliates, the company provides financial services, including banking, trust, and wealth management. It offers consumers and businesses a wide range of banking and related financial services, including checking, savings, certificates of deposit, and other depository services, as well as loans for commercial, industrial, residential mortgage, and consumer purposes. The company operates through two reportable operating segments: Wholesale Banking and Consumer Banking, with corporate support functions such as corporate treasury and others included in Corporate Other. It derives maximum revenue from the Wholesale Banking segment.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.